Switzerland's Roche Holding AG (ROG.EB) said Monday that a phase-3 trial of its Tecentriq and Avastin treatments showed positive results in patients with a type of advanced kidney cancer.
Roche said the IMmotion 151 trial met its co-primary endpoint, slowing the progression of kidney cancer and helping patients live longer.
Continue Reading Below
The study also showed the combination of Tecentriq and Avastin provided a statistically significant and clinically meaningful reduction in the risk of disease worsening or death, compared with patients who received Sunitinib--a conventional treatment--Roche said.
"No new safety signals were identified with the combination," the company added.
Roche said it was continuing to assess secondary endpoints associated with the study and that it would present the results at an oncology conference in 2018.
Write to Nathan Allen at firstname.lastname@example.org
(END) Dow Jones Newswires
December 11, 2017 01:44 ET (06:44 GMT)